SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma

Study Design Overview

This is a prospective, multicenter, observational real-world study conducted at approximately 16 hospitals across China. Patients with completely resected (R0), T1-T3, N0M0 sinonasal adenoid cystic carcinoma (ACC) are enrolled after surgery. The study does not randomize patients; instead, treatment assignment (postoperative radiotherapy vs. observation alone) is determined by shared decision-making between the patient and the attending physician, reflecting routine clinical practice.

Treatment Groups

Radiotherapy group: Patients receive intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT) at a dose of 60-66 Gy to the high-risk clinical target volume (CTV1) and 54-60 Gy to the low-risk CTV2, starting within 4-6 weeks after surgery.

Observation group: Patients undergo regular follow-up without postoperative radiotherapy.

All patients receive the same standardized follow-up schedule and supportive care.

Sample Size and Power

A total of 200 patients (approximately 100 per group) are planned. Based on historical data from the lead center (3-year disease-free survival [DFS] of 70% in the radiotherapy group vs. 62% in the observation group, corresponding to a hazard ratio [HR] of 1.35), with a two-sided alpha of 0.05 and power of 80%, this sample size is expected to yield approximately 80-90 DFS events over the 3-year follow-up period.

Statistical Methods

Primary analysis: The non-inferiority of observation versus radiotherapy for 3-year DFS will be assessed using a Cox proportional hazards model with inverse probability of treatment weighting (IPTW) based on propensity scores. The non-inferiority margin is set at HR = 1.35 (upper bound of the 95% confidence interval must be <1.35).

Propensity score model: Includes age, sex, T stage (T1/T2 vs. T3), tumor site, histologic subtype (cribriform/tubular proportion), perineural invasion, margin distance, Ki-67 index, ECOG performance status, and comorbidities.

Sensitivity analyses: Multivariable Cox regression, propensity score matching (1:1, caliper 0.2), instrumental variable analysis (using center preference as the instrument), and E-value analysis will be performed.

Secondary endpoints: Overall survival (1, 3, 5 years), 1-year and 5-year DFS, local control rate, distant metastasis rate, quality of life (EORTC QLQ-C30 and QLQ-H&N35), and treatment-related toxicity (CTCAE v5.0) will be compared between groups using appropriate methods (Kaplan-Meier, log-rank test, or competing risk models).

Data Collection and Follow-up

Baseline data: Demographics, clinical and pathologic characteristics, surgical details.

Follow-up visits: Every 4 months for the first 2 years, every 6 months for years 3-5, and annually thereafter. Each visit includes physical examination, laboratory tests, and toxicity assessment.

Imaging: Contrast-enhanced MRI every 6 months for the first 3 years and annually for years 4-5 (or whenever clinically indicated). Chest CT annually.

All suspected recurrences are centrally reviewed by a blinded independent central review (BICR) committee using RECIST 1.1 criteria.

Quality Control and Data Monitoring

An independent Data Monitoring Committee (DMC) comprising clinical experts, biostatisticians, and ethicists will review safety data (serious adverse events) every 6 months and overall data quality annually.

Central pathology review confirms the diagnosis and histologic subtype for all enrolled patients.

Electronic data capture (EDC) with source data verification (SDV) will be used. Ethics and Dissemination

The study protocol has been approved by the Ethics Committee of the Eye & ENT Hospital of Fudan University (approval number: 2026042-1). All participating centers will obtain local ethics approval. Written informed consent will be obtained from all patients. Results will be submitted for publication in peer-reviewed journals regardless of the outcome.

Inclusion criteria

• Age ≥18 years and ≤75 years.
• Histologically confirmed adenoid cystic carcinoma of cribriform or tubular type (solid type excluded) by central pathology review.
• Completed radical surgical resection with postoperative pathology confirming R0 resection (negative microscopic margins).
• Tumor stage T1, T2, or T3 according to AJCC 8th edition, with N0 and M0 status.
• Tumor originating from the nasal cavity or paranasal sinuses (excluding primary salivary gland tumors metastatic to this region).
• ECOG performance status 0 or 1.
• Adequate bone marrow, liver, and kidney function within 14 days before enrollment:

• Absolute neutrophil count ≥1.5 × 10⁹/L, platelet count ≥100 × 10⁹/L, hemoglobin ≥90 g/L.
• Total bilirubin ≤1.5 × upper limit of normal (ULN); AST and ALT ≤2.5 × ULN.
• Serum creatinine ≤1.5 × ULN or calculated creatinine clearance ≥60 mL/min (Cockcroft-Gault formula).
• Willing and able to provide written informed consent.

Exclusion criteria

• Tumor stage T4, or presence of regional lymph node metastasis (N+), or distant metastasis (M1).
• Postoperative pathology showing positive margins (R1 or R2).
• Prior head and neck radiotherapy.
• Concurrent active malignancy other than adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix.
• Uncontrolled serious concomitant disease (e.g., unstable angina, recent myocardial infarction, uncontrolled hypertension).
• Pregnant or breastfeeding women, or women of childbearing age not using effective contraception.
• Psychological, social, or geographic factors that may interfere with study compliance.